Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | STAT6 | P42226 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25331476 | 1.00 | APLNR (0.34) | APLNRFFAR3MAPK1TP53NFKB1 | |
| SCHEMBL25331473 | 1.00 | APLNR (0.34) | APLNRFFAR3MAPK1TP53NFKB1 | |
| SCHEMBL31530488 | 1.00 | APLNR (0.34) | APLNRFFAR3MAPK1TP53NFKB1 | |
| SCHEMBL16843480 | 0.77 | CYP3A4 (0.43) | LMNASMN1; SMN2NPSR1 | |
| SCHEMBL21048297 | 0.77 | CYP3A4 (0.43) | LMNASMN1; SMN2NPSR1 | |
| SCHEMBL27045965 | 0.76 | TSHR (0.33) | APLNRFFAR3CYP2C19LMNA | |
| SCHEMBL25332318 | 0.74 | CYP3A4 (0.33) | APLNRFFAR3LMNASMN1; SMN2NPSR1 | |
| SCHEMBL20364187 | 0.74 | TSHR (0.32) | LMNASMN1; SMN2NPSR1 | |
| SCHEMBL19557150 | 0.74 | TSHR (0.32) | LMNASMN1; SMN2NPSR1 | |
| SCHEMBL19557120 | 0.72 | F10 (0.36) | HIF1ALMNASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030033-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180194721-A1 | DIFLUOROALKYLCYCLOPROPYL AMINO ACIDS AND ESTERS, AND SYNTHESES THEREOF | ABBVIE INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-9862728-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9809534-B1 | Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9655944-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9562058-B2 | Crystalline forms of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2016-12-15 | — | — | US | disclosed |
| US-9440991-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9296782-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | APLNR 4758/4885FFAR3 4759/4885MAPK1 1363/4885 |
| US-20150175625-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | HAVCR2, IFNAR1, ZC3HAV1 | APLNR 4217/4885FFAR3 1782/4885MAPK1 2545/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | APLNR 4663/4885FFAR3 3062/4885MAPK1 3693/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | APLNR 4641/4885FFAR3 2710/4885MAPK1 3681/4885 |
| US-10030033-B2 | Synthesis of an antiviral compound | EIF2AK2, MAVS, SARS1 | APLNR 4758/4885FFAR3 4759/4885MAPK1 1363/4885 |
| US-20180194721-A1 | DIFLUOROALKYLCYCLOPROPYL AMINO ACIDS AND ESTERS, AND SYNTHESES THEREOF | DNPEP, PEPD, ANPEP | APLNR 1683/4885FFAR3 1496/4885MAPK1 2801/4885 |
| US-20160361375-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | APLNR 4641/4885FFAR3 2710/4885MAPK1 3681/4885 |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | APLNR 3213/4885FFAR3 4724/4885MAPK1 2037/4885 |
| US-20150175626-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | APLNR 4758/4885FFAR3 4759/4885MAPK1 1363/4885 |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | HAVCR2, IFNAR1, ZC3HAV1 | APLNR 4217/4885FFAR3 1782/4885MAPK1 2545/4885 |
| US-20140274884-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, LIPC | APLNR 4687/4885FFAR3 2973/4885MAPK1 2824/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | APLNR 4641/4885FFAR3 2710/4885MAPK1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.